Artiva Biotherapeutics, Inc. ARTV 深 沪
等待开盘 10-07 09:30:00 美东时间
7.24
+0.110
+1.54%
华盛通- 最 高12.08
- 今 开7.12
- 成交量 23.47万股
- 最 低 6.5195
- 昨 收 7.13
- 总市值 0
- 52周最高 14.53
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 2.96
- 委 比 -50.00%
- 总股本 --
- 历史最高 17.305
- 量 比 0.93
- 振 幅 77.99%
- 历史最低 1.47
- 每 手 1
- 风险率 2.88%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Artiva Biotherapeutics Announces Data Presentations On Allogenic NK Cell Therapy June 3-6
Abstracts:LB0003Oral PresentationAB-101, an Outpatient-Administered Allogeneic NK Cell Therapy Combined with Rituximab, Generates Robust Clinical Efficacy Responses Comparable with Autologous CAR T in 31 Patients with
05-20 04:07
Artiva Biotherapeutics Stock Slides Despite Positive Trial Data
Artiva Biotherapeutics shares fall after Phase 2a rheumatoid arthritis data and a $300 million private placement announcement.
05-09 00:20
Artiva Biotherapeutics Suspends Share Offering Under Sales Agreement With Leerink Partners
On May 8, 2026, the Company delivered written notice to Leerink Partners LLC ("Leerink") that the Company has suspended and is not offering any shares of its common stock pursuant to the prospectus filed with the
05-08 18:44
Artiva Biotherapeutics Q1 EPS $(0.95) Misses $(0.89) Estimate
Artiva Biotherapeutics (NASDAQ:ARTV) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0.89) by 6.74 percent. This is a 14.46 percent decrease over losses of $(0.83) per
05-08 18:33
Artiva Biotherapeutics Appoints Thad Huston CFO,
Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and
02-24 21:02
US Stocks Mixed; NY Manufacturing Activity Dips In December
U.S. stocks traded mixed this morning, with the Dow Jones index gaining around ...
2025-12-15 23:02
亚洲权威消费科技与室内设计盛会 "设计深圳"2025将于9月盛大开展
深圳2025年8月4日 /美通社/ --第三届"设计深圳Design Shenzhen"将于2025年9月18日至21日在深圳会展中心举办。作为亚洲...
2025-08-04 20:14
Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference
Artiva Biotherapeutics announced its participation in the Jefferies Global Healthcare Conference with a fireside chat and investor meetings. The company focuses on developing cell therapies for autoimmune diseases and cancers, particularly through its AlloNK® program targeting B-cell driven conditions. Artiva was founded in 2019 as a spinout from GC Cell, leveraging its NK cell manufacturing technology.
2025-05-28 20:05
Artiva Biotherapeutics Reports Wider Q2 Loss, No Revenue
05:31 PM EDT, 08/29/2024 (MT Newswires) -- Artiva Biotherapeutics (ARTV) reported a Q2 loss late Thursday of $22 per diluted share, wider than a loss of $14.09 a year earlier. Four analysts surveyed by Capital IQ expected a loss of $4.40. No revenue for the quarter ended June 30 was reported. Revenu...
2024-08-30 05:31
Artiva Biotherapeutics Q2 EPS $(22.00) Down From $(14.09) YoY
Artiva Biotherapeutics (NASDAQ:ARTV) reported quarterly losses of $(22.00) per share. This is a 56.14 percent decrease over losses of $(14.09) per share from the same period last year.
2024-08-30 04:14
